Report Overview

The Uterine Fibroid Treatment market in the EU was valued at $XX billion in 2019 and will reach $XX billion in 2028, providing a CAGR of XX% during the forecast period of 2019-2028

Uterine fibroids are the most common benign tumors in women. Treatment is only necessary if the fibroids cause pain and bleeding due to their size and position. Minimally-invasive fibroid embolization is a gentle, efficient, and long-lasting treatment for their removal, leaving the uterus intact. EMAs human medicines committee recommended restricting the use of medicines containing ulipristal acetate 5 mg (Esmya) as a result of cases of serious liver injury. The medicines can now only be used to treat uterine fibroids in premenopausal women for whom surgical procedures (including uterine fibroid embolization) are not appropriate or have not worked



Market Growth Drivers

The surging cases and improving awareness of Uterine Fibroid would drive market growth. The case is further bolstered by the rising availability of efficient and innovative therapies and the high purchasing power of women in the country. Patients are increasingly opting for minimally or non-invasive uterine fibroid procedures, for which players are focusing on developing types of devices that ensure the same. The high preference for these procedures is due to the fact that these ensure reduced post-operative pain and also mean faster recovery. Various initiatives are taken up by the government as well as private firms to raise the awareness level among the mass about early uterine fibroids diagnosis as well as treatment